Company withdraws MAA for vosaroxin in AMLMay 3, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Heavily promoted drugs provide less ‘health value,’ study suggestsMay 3, 2017ThrombosisPharmacyRelated Issues
FDA approves first ready-to-use oral solution of methotrexateMay 2, 2017Leukemia, Myelodysplasia, TransplantationPediatricsPharmacyALL
Drug receives orphan designation for AMLMay 2, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
FDA approves midostaurin to treat FLT3+ AML, advanced SMMay 1, 2017Leukemia, Myelodysplasia, TransplantationPharmacyAML
Program allows select Europeans access to belinostatApril 27, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin Lymphoma
FDA issues warnings about illegal ‘anticancer’ productsApril 26, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaPharmacyRelated Issues
CHMP recommends inotuzumab ozogamicin for adult ALLApril 24, 2017Leukemia, Myelodysplasia, TransplantationPharmacyALL
CHMP recommends approval for rituximab biosimilarApril 23, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
CAR T-cell therapy receives breakthrough designationApril 19, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
